Neurizon Therapeutics Limited, a clinical-stage biotech focused on neurodegenerative diseases, announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its lead investigational therapy, NUZ-001. This milestone clears the way for Phase 2/3 development of NUZ-001 as part of the HEALEY ALS Platform Trial, expected to begin Q4 2025.
Key Highlights
- Regulatory Milestone: FDA clearance of the IND application for NUZ-001 enables the initiation of pivotal clinical studies for ALS.
- Platform Strategy: The IND establishes a regulatory framework for safety, manufacturing, and clinical design, reducing regulatory risk, shortening timelines, and enabling expansion into future indications.
- Strong Preclinical and OLE Data: NUZ-001 is supported by robust TDP-43 preclinical data and encouraging survival outcomes from the Open-Label Extension (OLE) study in ALS patients.
- Collaboration with HEALEY ALS Platform Trial: Neurizon is working with Mass General Hospital (MGH) to file a protocol amendment to incorporate NUZ-001’s regimen, with patient enrollment anticipated in Q4 2025.
CEO Comment
"The FDA’s clearance marks a significant step in our mission to bring NUZ-001 closer to ALS patients. This milestone reflects our commitment to rigorous scientific and clinical development, as well as the support of KOLs and patient advocacy groups. We believe NUZ-001 has the potential to meaningfully slow the progression of this devastating disease."
- Dr. Michael Thurn, MD, CEO of Neurizon.
About NUZ-001
NUZ-001 is Neurizon’s lead investigational therapy for amyotrophic lateral sclerosis (ALS), the most common form of motor neuron disease. As a platform molecule, NUZ-001’s regulatory clearance supports future development programs while providing a validated framework for clinical design, safety, and manufacturing.
About Neurizon Therapeutics
Neurizon Therapeutics Limited is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. The company’s mission is to accelerate patient access to innovative therapies and develop potential disease-modifying treatments for ALS and related conditions.
